Indium (111In) biciromab

From WikiMD's WELLNESSPEDIA


Indium (111In) biciromab
INN
Drug class
Routes of administration
Pregnancy category N/A
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status Withdrawn
CAS Number 138783-13-8
PubChem
DrugBank
ChemSpider none
KEGG D03111

Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]

References[edit]

  1. King, David J.."Recombinant antibodies for the diagnosis and therapy of human disease".Current Opinion in Drug Discovery & Development.1999;2(2)
    112.
  2. Answers.com: Centocor Ortho Biotech Products, L.P.
  3. DiagnosticImaging.com: Centocor withdraws imaging agent applications



Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.